CHICAGO--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced the results of an in vitro study of their Obagi Professional-C and Obagi-C Rx Serums today at the American Academy of Dermatology’s Summer Academy Meeting in Chicago. The data show that Obagi-C Rx Serum (4% hydroquinone, 10% L-ascorbic acid) provided a more than 10-fold greater absorption of vitamin C than the leading competitive product, Skinceuticals® 20%. The Obagi Professional-C Serum (20%) resulted in a more than 5-fold greater absorption of vitamin C than the leading competitive product.
